11 studies found for:    jennerex
Show Display Options
Rank Status Study
1 Unknown  A Study of Recombinant Vaccinia Virus Prior to Sorafenib to Treat Unresectable Primary Hepatocellular Carcinoma
Condition: Carcinoma, Hepatocellular
Intervention: Drug: JX-594 followed by sorafenib
2 Active, not recruiting Recombinant Vaccinia Virus Administered Intravenously in Patients With Metastatic, Refractory Colorectal Carcinoma
Conditions: Colorectal Carcinoma;   CRC
Interventions: Biological: JX-594;   Drug: Irinotecan
3 Completed A Study of Recombinant Vaccinia Virus to Treat Unresectable Primary Hepatocellular Carcinoma
Condition: Carcinoma, Hepatocellular
Intervention: Genetic: JX-594: Recombinant vaccinia virus (TK-deletion plus GM-CSF)
4 Unknown  A Phase 2b Study of Modified Vaccinia Virus to Treat Patients Advanced Liver Cancer Who Failed Sorafenib
Conditions: Hepatocellular Carcinoma;   Liver Cancer;   HCC
Interventions: Biological: JX-594 recombinant vaccina GM-CSF;   Other: Best Supportive Care
5 Completed A Study of Recombinant Vaccinia Virus to Evaluate the Safety and Efficacy of a Transdermal Injection Within the Tumor of Patients With Primary or Metastatic Hepatic Carcinoma
Condition: Neoplasms, Liver
Intervention: Genetic: JX-594: Recombinant vaccinia virus (TK-deletion plus GM-CSF)
6 Unknown  Safety Study of Recombinant Vaccinia Virus Administered Intravenously in Patients With Metastatic, Refractory Colorectal Carcinoma
Condition: Carcinoma, Colorectal
Intervention: Drug: Recombinant Vaccinia GM-CSF; RAC VAC GM-CSF (JX-594)
7 Unknown  Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors
Conditions: Melanoma;   Lung Cancer;   Renal Cell Carcinoma;   Squamous Cell Carcinoma of the Head and Neck
Intervention: Drug: Recombinant Vaccinia GM-CSF; RAC VAC GM-CSF (JX-594)
8 Unknown  A Phase 2a Study of Modified Vaccinia Virus to Treat Sorafenib-naïve Advanced Liver Cancer
Condition: Hepatocellular Carinoma
Intervention: Biological: JX-594 recombinant vaccina GM-CSF
9 Completed A Study of Recombinant Vaccinia Virus to Treat Malignant Melanoma
Condition: Melanoma
Intervention: Biological: JX-594
10 Unknown  Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors in Pediatric Patients
Conditions: Neuroblastoma;   Rhabdomyosarcoma;   Lymphoma;   Wilm's Tumor;   Ewing's Sarcoma
Intervention: Drug: Recombinant Vaccinia GM-CSF; RAC VAC GM-CSF (JX-594)
11 Terminated Neoadjuvant Study of Recombinant Vaccinia Virus to Treat Metastatic Colorectal Carcinoma in Patients Undergoing Complete Resection of Liver Tumors
Condition: Colorectal Carcinoma
Intervention: Drug: Recombinant Vaccinia GM-CSF; RAC VAC GM-CSF (JX-594)

Indicates status has not been verified in more than two years